Hi John, I think it is a little unfair, what y

Hi John,

I think it is a little unfair, what you write about Oral-Lyn.
Oral-lyn already has a restricted approval for Oral-lyn under the so called FDA's "investigational new drug" (IND) program, which has - in the history of this program so far always lead to a full FDA approval. IND means GNBT can already sell Oral-lyn to a group of people, who are diabetics but cannot give themselves regular injections, such as "hemopgiliacs", who cannot stop the bleeding of a wound.
The reformulation is already done and GNBT has just postponed the necessary clinical re-trials (full phase III, in worst case), until the uplisting to Nasdaq is achieved, because then the financing options will be significantly better. So everything depends on this damned uplisting. Once that is achieved, it appears as if the future looks bright ahead. Everybody in this company knows this and I am sure they do everything in their power to get this biggest goal achieved.